Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study - 15/07/15
Funding sources: Biocon Limited funded this study and supplied drug. Employees of Biocon Limited, its affiliates, or its designees designed the study and analyzed data. The medical writing team of Biocon Limited assisted the authors in preparing this manuscript. |
|
Statement on prior presentation: The contents of this manuscript have been presented at the 94th Annual Meeting of the British Association of Dermatologists, July 1-3, 2014, SECC, Glasgow, UK. |
|
Conflicts of interest: SD, DSK, LB, CRS, UK, SG, NS, DVSP, MGG, TNR, VG, TKS, AS, RB, MK, NP, RS, KSK, DP, and GM conducted and collected the trial data; they received honoraria. RM, AB, and EM are Biocon Research Limited employees. EM, RM, DSK, and LB designed the study. The study was approved and reviewed by the Institutional Review Board. |
Vol 73 - N° 2
P. 331 - août 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?